To address this problem we have developed the SubType Classifier that combines whole genome sequencing (WGS) data and machine learning algorithms supporting molecular-based breast cancer subtype classification.
At the ESMO Breast Cancer Congress 2022, we present the results that confirm that comprehensive genomic data supports the breast cancer subtype classification, reaviling deeper insights into tumor biology. An increasingly better understanding of the topic of breast cancer brings us closer to achieving better results in treatment and survival rate. If an annual mortality reduction of 2.5% per year occurs worldwide, 2.5 million breast cancer deaths would be avoided between 2020 and 2040*. (*WHO) At MNM – taking part in improving BC treatment outcomes is our main goal. Knowledge-based WGS data analysis and pharmaceuticals trials allows delivering verification of treatment way that could match the best.
